UnitedHealth Group (UNH) is back in focus after raising its 2026 adjusted EPS guidance and reporting stronger than expected first quarter results, alongside a supportive Medicare Advantage rate decision.
See our latest analysis for UnitedHealth Group.
Recent news has been reflected in the share price, with a 1-day share price return of 1.57% and a 30-day share price return of 9.45%, contributing to a 37.59% share price return over 90 days. However, the 3-year total shareholder return remains down 14.42%, suggesting short term momentum has improved after a difficult few years.
If UnitedHealth’s rebound has you rethinking where healthcare meets technology, it could be a good moment to broaden your search with 34 healthcare AI stocks
After such a sharp rebound, with the stock still trading at an intrinsic value estimate that suggests a wide discount and only a small gap to the average analyst target, you have to ask yourself: Is there real value left here, or is the market already pricing in the next leg of growth?
Most Popular Narrative: 20.2% Undervalued
At a last close of $388.47 against a narrative fair value of $486.86, UnitedHealth Group is framed as materially undervalued, with that gap hinging on how its core businesses scale over time.
UNH benefits from several industry tailwinds:
Expanding Premium Base: UNH’s premium base continues to grow, contributing to its revenue growth.
Want to see what is baked into that valuation gap? The narrative leans heavily on premium growth, stable margins and a richer mix from Optum.
Result: Fair Value of $486.86 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on a fragile balance, as regulatory changes or sharper competition in insurance and pharmacy services are both capable of quickly eroding that perceived discount.
Find out about the key risks to this UnitedHealth Group narrative.
Another View: Market Multiple Sends A Different Signal
That 20.2% undervaluation story based on fair value sits beside a more cautious read from the P/E ratio. UnitedHealth Group trades on 29.3x earnings, richer than the US Healthcare industry at 24.6x, although below peers at 33.7x and under a fair ratio estimate of 39.7x.
In practice, that mix suggests the stock already carries a premium versus the sector, yet still leaves room if the market leans closer to the fair ratio. The question is whether you see that premium as protection or extra valuation risk.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of optimism and caution feels familiar, do not wait on others to frame it for you. Weigh both sides using 3 key rewards and 2 important warning signs
Looking for more investment ideas?
If you stop with just one stock, you risk missing opportunities that could better match your goals, so broaden your watchlist with a few focused screens.
- Target potential bargains by scanning companies that appear mispriced relative to their fundamentals using 49 high quality undervalued stocks.
- Strengthen your income focus by checking out businesses that offer reliable payouts through 10 dividend fortresses.
- Reduce potential shocks by reviewing companies with steadier financial profiles via the 66 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com